Does Ozempic Interact With Other Medications? What the Science Actually Says

When a drug reshapes how your body processes food, slows the movement of everything through your gut, and influences insulin secretion, blood pressure, and even brain chemistry, it would be surprising if it didn’t interact with other medications. Yet many men who start semaglutide — whether as Ozempic for type 2 diabetes or Wegovy for weight loss — get surprisingly little counseling on drug interactions before their first injection. That gap in information can be dangerous, and in some cases, clinically significant.

The science here is nuanced. A comprehensive 2025 pharmacokinetic review published in Drug Design, Development and Therapy found that while semaglutide and other GLP-1 receptor agonists do not appear to cause the classic enzyme-mediated drug-drug interactions that many medications do, they carry a distinct and underappreciated category of interaction — one driven entirely by their mechanism of action, specifically the way they dramatically slow gastric emptying. That distinction matters, because it means the standard checklist your pharmacist runs won’t necessarily catch the interactions that could affect you most.

This article breaks down exactly what we know, what we don’t, and what every man on Ozempic — or considering it — needs to understand before stacking it with other medications, supplements, or substances.

How Ozempic’s Mechanism Creates Drug Interactions

Most drug interactions you’ve heard about involve the liver’s cytochrome P450 enzyme system — the biochemical machinery that metabolizes the majority of prescription medications. One drug speeds up or slows down these enzymes, altering how quickly another drug gets processed. Warfarin and statins, antibiotics and antifungals — these are classic examples. The good news for semaglutide users is that the 2025 pharmacokinetic review confirmed that clinically significant enzyme- or transporter-mediated drug-drug interactions have not been reported for GLP-1 receptor agonists. Semaglutide is a large peptide molecule that undergoes proteolytic degradation rather than hepatic metabolism, so it largely sidesteps that whole system.

But what it doesn’t sidestep is gastric emptying. One of semaglutide’s primary mechanisms is slowing the rate at which food and liquids leave the stomach and enter the small intestine. This is part of why it suppresses appetite so effectively — the stomach stays fuller for longer. The problem is that nearly every oral medication you take relies on gastric emptying for absorption. If your stomach empties more slowly, some drugs reach peak concentration in the bloodstream later, at lower levels, or for a longer duration than expected. The same 2025 review notes that while most studies have found these gastric-emptying-related interactions to be clinically insignificant for many medications, two specific exceptions stood out: oral contraceptives following tirzepatide administration, and levothyroxine following oral semaglutide, both of which showed significant changes in drug exposure warranting close monitoring.

Levothyroxine is worth pausing on specifically. It is one of the most commonly prescribed medications in the United States, used by men and women alike for hypothyroidism. It requires precise, consistent absorption — ideally taken on an empty stomach, with nothing interfering for at least 30 to 60 minutes. If you’re taking oral semaglutide (Rybelsus) alongside levothyroxine, the slowed gastric motility could meaningfully alter how much thyroid hormone actually makes it into your bloodstream. That could leave your thyroid levels underdosed and your energy, metabolism, and body composition all worse off as a result. If you take levothyroxine and are prescribed oral semaglutide, this is a conversation worth having directly with your prescribing physician before your first dose.

The High-Stakes Interactions: Insulin, Blood Pressure Drugs, and Alcohol

For men managing type 2 diabetes alongside cardiovascular disease or other metabolic conditions, the drug interaction landscape gets more complex — and more consequential. The most immediately dangerous interaction is between semaglutide and insulin or insulin secretagogues like sulfonylureas. Semaglutide lowers blood glucose through multiple pathways: stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. When combined with medications that independently force insulin release — especially sulfonylureas like glipizide or glimepiride — the additive effect can push blood sugar too low, resulting in hypoglycemia. This isn’t a theoretical concern. Clinical guidelines universally recommend reducing sulfonylurea doses when initiating a GLP-1 receptor agonist, and your doctor should be monitoring this closely. If you’re on one of these combinations and experience shakiness, cold sweats, confusion, or rapid heartbeat, treat it as a medical emergency.

The cardiovascular picture is actually encouraging when it comes to how semaglutide interacts with heart disease management broadly. A prespecified analysis of the SELECT trial published in The Lancet in 2024 found that once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events and composite heart failure endpoints in patients with atherosclerotic cardiovascular disease and obesity — regardless of whether those patients had heart failure with preserved or reduced ejection fraction. This is clinically meaningful: it suggests that semaglutide can be used alongside standard cardiovascular pharmacotherapy (statins, ACE inhibitors, beta-blockers, diuretics) without undermining those therapies, and may in fact complement them. That said, semaglutide can influence blood pressure, and men already taking antihypertensive medications should have their blood pressure monitored more frequently when initiating the drug, particularly during the titration phase when weight loss begins accelerating.

Then there’s alcohol — a substance most men don’t think of as a pharmacological interaction risk, but one that deserves serious attention here. A 2025 randomized clinical trial published in JAMA Psychiatry found that low-dose semaglutide significantly reduced alcohol craving, drinks per drinking day, and peak breath alcohol concentration in adults with alcohol use disorder. That’s genuinely promising from a therapeutic standpoint. But the flip side is that semaglutide appears to pharmacologically alter the brain’s reward response to alcohol. For a man who drinks regularly — even moderately — this interaction could manifest as a dramatically lower tolerance to alcohol’s effects, meaning the same number of drinks hits harder and faster. Add to that the nausea that many men already experience on semaglutide, and alcohol can become a much more destabilizing substance than it was before starting treatment. The practical takeaway: if you’re on Ozempic or Wegovy, give your alcohol tolerance an honest reassessment and be conservative, especially in social situations where you might normally drink more freely.

Medications That Deserve Special Attention on Ozempic

Beyond the headline interactions, there is a broader category of medications worth monitoring carefully when on semaglutide — not because the interactions are definitively dangerous, but because the physiological changes semaglutide drives can shift how these drugs behave over time.

Anticoagulants like warfarin are one example. Warfarin has a notoriously narrow therapeutic window and is highly sensitive to changes in diet, body weight, and metabolism. As semaglutide drives significant weight loss — the OASIS 1 trial demonstrated a mean body weight reduction of 15.1% over 68 weeks with oral semaglutide 50 mg versus 2.4% with placebo — the pharmacokinetics of warfarin can shift meaningfully. A man who loses 20 to 30 pounds while on warfarin may require dose adjustments to maintain his INR within the therapeutic range. This isn’t unique to semaglutide specifically, but the magnitude and pace of weight loss it produces makes it a more pressing concern than with lifestyle-driven weight loss alone. INR monitoring should be more frequent during active weight loss phases.

Metformin is commonly co-prescribed with semaglutide in the management of type 2 diabetes, and the combination is generally well-tolerated. However, both drugs can cause gastrointestinal side effects — nausea, diarrhea, stomach discomfort — and the combination can amplify these significantly, particularly during the dose escalation phase of semaglutide. Men dealing with significant GI side effects on the combination should speak with their physician about timing doses differently or temporarily adjusting metformin dosing until the semaglutide titration stabilizes.

Statins — the most widely prescribed cardiovascular medications in the world — do not appear to have a clinically significant pharmacokinetic interaction with semaglutide, and this combination is extremely common given the cardiovascular profile of the population most often prescribed GLP-1 receptor agonists. However, statin metabolism can be subtly influenced by changes in body composition and liver fat over time, and since semaglutide reduces hepatic fat substantially, it’s worth tracking liver enzymes periodically if you’re on a statin and initiating semaglutide simultaneously.

For men taking psychiatric medications — antidepressants, antipsychotics, mood stabilizers — the interaction picture is less well-characterized but not without relevance. Some antipsychotics (like olanzapine and quetiapine) are associated with significant weight gain and metabolic dysfunction, which creates both an opportunity and a complexity when adding semaglutide. Semaglutide may counteract some of the metabolic effects of these drugs, but changes in gastric emptying could alter the absorption of oral psychiatric medications, and the nausea side effects of semaglutide can complicate adherence to medications that also carry GI burden. Anyone managing psychiatric conditions alongside GLP-1 therapy should have their mental health care team and prescribing physician in close communication.

One area that remains genuinely underdeveloped in the research is how semaglutide interacts with common over-the-counter medications and supplements. Aspirin, NSAIDs, proton pump inhibitors, and various supplements including magnesium, zinc, and fat-soluble vitamins are widely used by men in the health-conscious demographic most likely reading this article. The gastric-emptying effect of semaglutide could theoretically alter the absorption of fat-soluble vitamins A, D, E, and K if dietary fat intake is significantly reduced — which is common when appetite suppression kicks in on semaglutide. The 2025 pharmacokinetic review acknowledges that alterations in fat mass, changes in cytochrome P450 activity driven by weight loss, and shifts in glomerular filtration rate are all factors that can influence pharmacokinetics during GLP-1 therapy, but notes that the drug interactions mediated by these factors remain poorly understood and require further investigation. That’s a clinical research gap, not reassurance.

There’s also an emerging conversation around how semaglutide might interact with the skin and collagen-related physiology, which while not a drug-drug interaction in the pharmacokinetic sense, has real implications for men who take collagen peptides, retinoids, or topical skincare ingredients. A 2025 review in Endocrine found that GLP-1 receptor agonists may accelerate skin aging through mechanisms beyond just fat loss — including reducing the protective cytokine output of adipose-derived stem cells, promoting oxidative damage on fibroblasts, and indirectly reducing estrogen-mediated collagen stimulation from dermal white adipose tissue. This means semaglutide-driven weight loss may have downstream effects on skin structure and resilience that interact with how the skin responds to other interventions.

What This Means For You

If you’re on Ozempic or Wegovy, the most important thing to internalize is that the risk profile here is different from most drug interactions you’ve encountered before. You’re not dealing with a drug that will blow up your liver enzymes by competing for the same enzyme your statin uses. You’re dealing with a drug that fundamentally changes how your gut works, how your body weight shifts, and how your hormonal and metabolic environment operates — all of which can have downstream effects on medications that were calibrated to your previous physiology.

That means disclosure matters. Every medication and supplement you take — including aspirin, thyroid medications, blood pressure drugs, anticoagulants, psychiatric medications, and even regular alcohol consumption — should be part of a transparent conversation with your prescribing physician before you start semaglutide. Not because most of these will create dangerous interactions, but because the ones that do — hypoglycemia from sulfonylureas, destabilized INR on warfarin, reduced levothyroxine absorption — can do real harm before you realize something has shifted.

If you’re not on GLP-1 medications and are pursuing fat loss, better metabolic health, or cardiovascular fitness through diet, training, and lifestyle, most of this is academic for you — but the underlying principle applies universally. Any time you’re managing multiple medications or supplements simultaneously, the goal is to understand not just what each one does individually, but how they behave in combination with everything else in your system. That’s the kind of informed, systems-level thinking about your own health that separates men who get results from men who just follow protocols. Know what you’re taking, know why you’re taking it, and know who to call when the picture gets complicated.